FDA approves Sanofi's Tzield for children as young as one year old
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
April 22, 2026 1:05 AM EDTSanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3Tzield is the first disease-modifying therapy for children aged one year and above diagnosed with stage 2 T1DParis, April 22, 2026. The US Food and Drug Administration (FDA) has approved the supplemental biologic license application for Tzield... More
